Description
A member of the class of phosphonic acids that is methylphosphonic acid in which one of the methyl hydrogens has been replaced by a 2-(6-amino-9H-purin-9-yl)ethoxy group. An inhibitor of HIV-1 reverse transcriptase, the bis(t-butoxycarbonyloxymethyl) ester (dipivoxil ester) prodrug is used to treat chronic hepatitis B viral infection.
Chemical properties
| Chemical formula | Net charge | Average mass |
|---|---|---|
| C8H12N5O4P | 0 | 273.186 |
Nomenclature
| IUPAC | SMILES | InChI | InChIKey | Synonyms |
|---|---|---|---|---|
| {[2-(6-amino-9H-purin-9-yl)ethoxy]methyl}phosphonic acid | N1(C2=C(C(N)=NC=N2)N=C1)CCOCP(O)(=O)O | InChI=1S/C8H12N5O4P/c9-7-6-8(11-3-10-7)13(4-12-6)1-2-17-5-18(14,15)16/h3-4H,1-2,5H2,(H2,9,10,11)(H2,14,15,16) | SUPKOOSCJHTBAH-UHFFFAOYSA-N |
|
Citations
- Delmas, J, et al. 2002. Inhibitory effect of adefovir on viral DNA synthesis and covalently closed circular DNA formation in duck hepatitis B virus-infected hepatocytes in vivo and in vitro. Antimicrobial Agents and Chemotherapy. 46(2).
- Gómez-Coca, RB, et al. 2012. Extent of intramolecular π-stacks in aqueous solution in mixed-ligand copper(II) complexes formed by heteroaromatic amines and several 2-aminopurine derivatives of the antivirally active nucleotide analog 9-[2-(phosphonomethoxy)ethyl]adenine (PMEA). Chemistry & Biodiversity. 9(9).
- Herreros de Tejada Echanojáuregui, A, et al. 2005. Adefovir dipivoxil therapy in liver transplant recipients with lamivudine-resistant hepatitis B virus. Transplantation Proceedings. 37(3).
- Hiramatsu, R, et al. 2016. Bone Histology of Two Cases with Osteomalacia Related to Low-dose Adefovir. Internal Medicine (Tokyo, Japan). 55(20).
- Kim, HJ, et al. 2016. Comparison of the clinical outcomes between antiviral-naïve patients treated with entecavir and lamivudine-resistant patients receiving adefovir add-on lamivudine combination treatment. Clinical and Molecular Hepatology. 22(3).
- Köck, J, et al. 2003. Inhibitory effect of adefovir and lamivudine on the initiation of hepatitis B virus infection in primary tupaia hepatocytes. Hepatology (Baltimore, Md.). 38(6).
- Laho, T, et al. 2016. Effect of nonalcoholic steatohepatitis on renal filtration and secretion of adefovir. Biochemical Pharmacology. 115.
- Lee, HW, et al. 2016. Efficacy of switching from adefovir to tenofovir in chronic hepatitis B patients who exhibit suboptimal responses to adefovir-based combination rescue therapy due to resistance to nucleoside analogues (SATIS study). Clinical and Molecular Hepatology. 22(4).
- Lee, SH, et al. 2017. Tenofovir disoproxil fumarate monotherapy is superior to entecavir-adefovir combination therapy in patients with suboptimal response to lamivudine-adefovir therapy for nucleoside-resistant HBV: a 96-week prospective multicentre trial. Antiviral Therapy. 23(3).
- Li, Z, et al. 2016. Circulating kidney injury molecule-1 is a novel diagnostic biomarker for renal dysfunction during long-term adefovir therapy in chronic hepatitis B. Medicine. 95(44).
- Liao, S, et al. 2013. In vitro evaluation of 9-(2-phosphonylmethoxyethyl)adenine ester analogues, a series of anti-HBV structures with improved plasma stability and liver release. Archives of Pharmacal Research. 37(11).
- Lin, MT, et al. 2016. Comparison of the Efficacies and Safety of Combined Therapy between Telbivudine Plus Adefovir and Lamivudine Plus Adefovir in Patients with Hepatitis B Virus Infection in Real-World Practice. PloS One. 11(11).
- Lin, Y, et al. 2017. Adefovir dipivoxil-induced Fanconi syndrome and its predictive factors: A study of 28 cases. Oncology Letters. 13(1).
- Luo, Q, et al. 2016. Relationship between nephrotoxicity and long-term adefovir dipivoxil therapy for chronic hepatitis B: A meta-analysis. Medicine. 95(50).
- Pereira-Gómez, M, et al. 2016. Lamivudine/Adefovir Treatment Increases the Rate of Spontaneous Mutation of Hepatitis B Virus in Patients. PloS One. 11(9).
- Ruggiero, G, et al. 2016. Tenofovir disoproxil fumarate monotherapy maintains HBV suppression achieved by a "de novo" combination of lamivudine-adefovir: a pilot study. Le Infezioni in Medicina. 24(4).
- Shen, Y, et al. 2004. Selective inhibition of anthrax edema factor by adefovir, a drug for chronic hepatitis B virus infection. Proceedings of the National Academy of Sciences of the United States of America. 101(9).
- Song, BC, et al. 2017. Switch to tenofovir-based therapy or to continue adefovir-based therapy in CHB patients with suboptimal response to adefovir-based combination? Clinical and Molecular Hepatology. 22(4).
- Sparidans, RW, et al. 2000. Improved and simplified liquid chromatographic assay for adefovir, a novel antiviral drug, in human plasma using derivatization with chloroacetaldehyde. Journal of Chromatography. B, Biomedical Sciences and Applications. 736(1-2).
- Tian, L, et al. 2016. Effect of adefovir dipivoxil on T cell immune function in the treatment of chronic hepatitis B and hepatocirrhosis. Experimental and Therapeutic Medicine. 12(4).
- Vincenti, D, et al. 2017. Evolutionary trends of resistance mutational patterns of HBV reverse transcriptase over years (2002-2012) of different treatment regimens: The legacy of lamivudine/adefovir combination treatment. Antiviral Research. 143.
- Wei, Z, et al. 2016. Osteomalacia induced by long-term low-dose adefovir dipivoxil: Clinical characteristics and genetic predictors. Bone. 93.
- Yamamoto, T, et al. 2017. Hypophosphatemia predicts a failure to recover from adefovir-related renal injury after dose reduction in lamivudine-resistant hepatitis B patients. Hepatology Research : the Official Journal of the Japan Society of Hepatology. 47(12).
- Yang, S, et al. 2016. De novo entecavir+adefovir dipivoxil+lamivudine triple-resistance mutations resulting from sequential therapy with adefovir dipivoxil, and lamivudine. Annals of Clinical Microbiology and Antimicrobials. 15.
- Zhao, X, et al. 2017. Tenofovir and adefovir down-regulate mitochondrial chaperone TRAP1 and succinate dehydrogenase subunit B to metabolically reprogram glucose metabolism and induce nephrotoxicity. Scientific Reports. 7.